Structural Changes of Region 1-16 of the Alzheimer Disease Amyloid β-Peptide upon Zinc Binding and in Vitro Aging*
暂无分享,去创建一个
A. Mazur | S. Zirah | S. Rebuffat | A. Blond | S. Kozin | Pascale Debey | Isabelle Ségalas-Milazzo | P. Debey | Séverine Zirah | Sylvie Rebuffat | Alain Blond | I. Ségalas-Milazzo | M. Cheminant | Alexey K Mazur | Sergey A Kozin | Michel Cheminant
[1] M. Billeter,et al. MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.
[2] A. Gronenborn,et al. Determination of three-dimensional structures of proteins by simulated annealing with interproton distance restraints. Application to crambin, potato carboxypeptidase inhibitor and barley serine proteinase inhibitor 2. , 1988, Protein engineering.
[3] P. Mantyh,et al. Zinc‐Induced Aggregation of Human and Rat β‐Amyloid Peptides In Vitro , 1996 .
[4] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[5] H. Takeuchi,et al. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. , 2000, Biochemistry.
[6] C. Masters,et al. Alzheimer's Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits* , 2001, The Journal of Biological Chemistry.
[7] K. Wüthrich. NMR of proteins and nucleic acids , 1988 .
[8] J. D. Robertson,et al. Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.
[9] J R Ghilardi,et al. 1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. , 1995, Biochemistry.
[10] H. Bernstein. Recent changes to RasMol, recombining the variants. , 2000, Trends in biochemical sciences.
[11] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[12] Sang Won Suh,et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains , 2000, Brain Research.
[13] M. Billeter,et al. Calibration of the angular dependence of the amide proton-Cα proton coupling constants, 3JHNα, in a globular protein: Use of 3JHNα for identification of helical secondary structure , 1984 .
[14] W S Hancock,et al. Deamidation and isoaspartate formation during in vitro aging of recombinant tissue plasminogen activator. , 1994, The Journal of biological chemistry.
[15] P. Faller,et al. Characterization of the ZnII Binding to the Peptide Amyloid‐β1–16 linked to Alzheimer's Disease , 2005, Chembiochem : a European journal of chemical biology.
[16] M. Cronin,et al. Metals, toxicity and oxidative stress. , 2005, Current medicinal chemistry.
[17] N Go,et al. Calculation of protein conformations by proton-proton distance constraints. A new efficient algorithm. , 1985, Journal of molecular biology.
[18] G Klopman,et al. Solution structure of residues 1-28 of the amyloid beta-peptide. , 1994, Biochemistry.
[19] D. Kirschner,et al. Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils. , 1998, Biophysical journal.
[20] R. Tanzi,et al. The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. , 1994, The Journal of biological chemistry.
[21] T. Shirasawa,et al. Isoaspartate formation and neurodegeneration in Alzheimer's disease. , 2000, Archives of biochemistry and biophysics.
[22] Xudong Huang,et al. Zinc-induced Alzheimer’s Aβ1–40 Aggregation Is Mediated by Conformational Factors* , 1997, The Journal of Biological Chemistry.
[23] A. Takashima,et al. New Insights on How Metals Disrupt Amyloid β-Aggregation and Their Effects on Amyloid-β Cytotoxicity* , 2001, The Journal of Biological Chemistry.
[24] C. Barrow,et al. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. , 1999, Biochemistry.
[25] Math P. Cuajungco,et al. Zinc takes the center stage: its paradoxical role in Alzheimer’s disease , 2003, Brain Research Reviews.
[26] H. Shao,et al. Solution Structure Model of Residues 1−28 of the Amyloid β-Peptide When Bound to Micelles , 1998 .
[27] J. Gavilanes,et al. Characterization of pKa values and titration shifts in the cytotoxic ribonuclease alpha-sarcin by NMR. Relationship between electrostatic interactions, structure, and catalytic function. , 1998, Biochemistry.
[28] P. S. St George-Hyslop,et al. Immunotherapy for Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] C. Masters,et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. , 1994, Science.
[30] J. Tabet,et al. Zinc binding properties of the amyloid fragment Aβ(1–16) studied by electrospray-ionization mass spectrometry , 2003 .
[31] S. Clarke,et al. Succinimide formation from aspartyl and asparaginyl peptides as a model for the spontaneous degradation of proteins. , 1989, The Journal of biological chemistry.
[32] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[33] R. O’Hair. Gas phase acidities of the a amino acids , 1992 .
[34] K. Iwata,et al. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. , 2000, Journal of structural biology.
[35] J. Brewer,et al. Solution NMR Studies of the Aβ(1−40) and Aβ(1−42) Peptides Establish that the Met35 Oxidation State Affects the Mechanism of Amyloid Formation , 2004 .
[36] W. Halliday,et al. In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. , 1996, Biophysical journal.
[37] C. Barrow,et al. NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix----beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. , 1992, Biochemistry.
[38] H. Shao,et al. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. , 1999, Journal of molecular biology.
[39] Ashley I. Bush,et al. The metallobiology of Alzheimer's disease , 2003, Trends in Neurosciences.
[40] M. Balass,et al. N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies , 1998, Journal of Neuroimmunology.
[41] D. Westaway,et al. Examining the zinc binding site of the amyloid-β peptide , 2000 .
[42] A. Bush,et al. Amyloid-β Metal Interaction and Metal Chelation , 2005 .
[43] H. Mantsch,et al. Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form β-pleated sheets in vitro , 1994 .
[44] C. Cotman,et al. The Presence of Isoaspartic Acid in β-Amyloid Plaques Indicates Plaque Age , 1999, Experimental Neurology.
[45] D. Westaway,et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.
[46] P. Mantyh,et al. Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.
[47] R. Leapman,et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[48] G. H. Hoa,et al. Zinc binding to Alzheimer's Abeta(1-16) peptide results in stable soluble complex. , 2001, Biochemical and biophysical research communications.
[49] G. Siegel,et al. Efficacy of anti-Aβ antibody isotypes used for intracerebroventricular immunization in TgCRND8 , 2005, Neuroscience Letters.
[50] K. Beyreuther,et al. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. , 1995, European journal of biochemistry.
[51] Protein aging hypothesis of Alzheimer disease , 2000 .
[52] Mikito Yasuzawa,et al. Selection of novel structural zinc sites from a random peptide library , 2003, FEBS letters.
[53] R. Wetzel,et al. Structural features of the Abeta amyloid fibril elucidated by limited proteolysis. , 2001, Biochemistry.
[54] B. Solomon,et al. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. , 2003, Vaccine.
[55] L. Serpell,et al. X-ray fiber diffraction of amyloid fibrils. , 1999, Methods in enzymology.
[56] S. Clarke,et al. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. , 1987, The Journal of biological chemistry.
[57] A. Gronenborn,et al. Relationship between electrostatics and redox function in human thioredoxin: characterization of pH titration shifts using two-dimensional homo- and heteronuclear NMR. , 1992, Biochemistry.
[58] W. Chazin,et al. Identification of an isoaspartyl linkage formed upon deamidation of bovine calbindin D9k and structural characterization by 2D 1H NMR. , 1989, Biochemistry.
[59] F. Richards,et al. The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. , 1992, Biochemistry.
[60] Hai Lin,et al. Imaging real-time aggregation of amyloid beta protein (1–42) by atomic force microscopy , 2002, Peptides.
[61] D. Wishart,et al. The 13C Chemical-Shift Index: A simple method for the identification of protein secondary structure using 13C chemical-shift data , 1994, Journal of biomolecular NMR.
[62] Alexander D. MacKerell,et al. Computational Biochemistry and Biophysics , 2001 .
[63] M. Emmerling,et al. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. , 1998, Biochimica et biophysica acta.
[64] M. Przybylski,et al. Zinc binding agonist effect on the recognition of the β-amyloid (4–10) epitope by anti-β-amyloid antibodies , 2004 .
[65] D. Craik,et al. Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? , 1998, Biochemistry.
[66] T. Iwatsubo,et al. Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.
[67] M J Ball,et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. , 1993, The Journal of biological chemistry.
[68] C. Barrow,et al. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. , 1991, Science.
[69] S. Rebuffat,et al. Structure of trichorzianine A IIIc, an antifungal peptide from Trichoderma harzianum , 1985 .